CN116199785A - 多特异性抗体及其制备和使用方法 - Google Patents
多特异性抗体及其制备和使用方法 Download PDFInfo
- Publication number
- CN116199785A CN116199785A CN202310141321.2A CN202310141321A CN116199785A CN 116199785 A CN116199785 A CN 116199785A CN 202310141321 A CN202310141321 A CN 202310141321A CN 116199785 A CN116199785 A CN 116199785A
- Authority
- CN
- China
- Prior art keywords
- antibody
- domain
- antigen
- cells
- antibodies
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762524557P | 2017-06-25 | 2017-06-25 | |
| US62/524,557 | 2017-06-25 | ||
| PCT/US2018/039156 WO2019005639A2 (en) | 2017-06-25 | 2018-06-22 | MULTISPECIFIC ANTIBODIES AND METHODS OF PREPARATION AND USE THEREOF |
| CN201880039401.4A CN110831973B (zh) | 2017-06-25 | 2018-06-22 | 多特异性抗体及其制备和使用方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880039401.4A Division CN110831973B (zh) | 2017-06-25 | 2018-06-22 | 多特异性抗体及其制备和使用方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116199785A true CN116199785A (zh) | 2023-06-02 |
Family
ID=64742644
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310141321.2A Pending CN116199785A (zh) | 2017-06-25 | 2018-06-22 | 多特异性抗体及其制备和使用方法 |
| CN201880039401.4A Active CN110831973B (zh) | 2017-06-25 | 2018-06-22 | 多特异性抗体及其制备和使用方法 |
| CN202310141062.3A Pending CN116041530A (zh) | 2017-06-25 | 2018-06-22 | 多特异性抗体及其制备和使用方法 |
| CN202310922275.XA Pending CN116948035A (zh) | 2017-06-25 | 2018-06-22 | 多特异性抗体及其制备和使用方法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880039401.4A Active CN110831973B (zh) | 2017-06-25 | 2018-06-22 | 多特异性抗体及其制备和使用方法 |
| CN202310141062.3A Pending CN116041530A (zh) | 2017-06-25 | 2018-06-22 | 多特异性抗体及其制备和使用方法 |
| CN202310922275.XA Pending CN116948035A (zh) | 2017-06-25 | 2018-06-22 | 多特异性抗体及其制备和使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11787863B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3645049A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7399852B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20250024104A (cg-RX-API-DMAC7.html) |
| CN (4) | CN116199785A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2018295118B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3068045A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL313468A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11201912864SA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019005639A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20260008861A9 (en) * | 2017-06-25 | 2026-01-08 | Systimmune, Inc. | Anti-4-1bb antibodies and methods of making and using thereof |
| SG11201912865VA (en) * | 2017-06-25 | 2020-01-30 | Systimmune Inc | Multi-specific antibodies and methods of making and using thereof |
| JP7383605B2 (ja) * | 2017-06-25 | 2023-11-20 | システィミューン, インク. | 抗pd-l1抗体とその作製及び使用方法 |
| TW201904588A (zh) * | 2017-06-25 | 2019-02-01 | 美商西雅圖免疫公司 | 引導及導航控制蛋白質之製造及使用方法 |
| EP3773621A4 (en) * | 2018-03-27 | 2022-03-23 | Systimmune, Inc. | GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE |
| UY38701A (es) | 2019-05-21 | 2020-12-31 | Novartis Ag | Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas |
| AU2020279224B2 (en) | 2019-05-21 | 2024-12-05 | Novartis Ag | Trispecific binding molecules against BCMA and uses thereof |
| CN118580364A (zh) * | 2019-11-06 | 2024-09-03 | 西雅图免疫公司 | 制导和导航控制蛋白及其制备和使用方法 |
| EP3988568A1 (en) * | 2020-10-21 | 2022-04-27 | Numab Therapeutics AG | Combination treatment |
| CN118974091A (zh) * | 2022-04-11 | 2024-11-15 | 阿斯利康(瑞典)有限公司 | T细胞结合蛋白 |
| CA3262028A1 (en) * | 2022-07-15 | 2025-06-13 | Abl Bio Inc. | Anti-ROR1 antibodies, bispecific antibodies containing it, and their uses |
| CN120813602A (zh) * | 2022-12-20 | 2025-10-17 | 英克特诺治疗公司 | 用于治疗癌症的组合疗法 |
| US20240294651A1 (en) | 2023-01-30 | 2024-09-05 | Kymab Limited | Antibodies |
| CN116143934B (zh) * | 2023-03-21 | 2023-07-25 | 诺赛联合(北京)生物医学科技有限公司 | 一种干细胞外泌体提取试剂盒及其应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102448985A (zh) * | 2009-05-27 | 2012-05-09 | 霍夫曼-拉罗奇有限公司 | 三或四特异性抗体 |
| US20160355600A1 (en) * | 2014-12-22 | 2016-12-08 | Xencor, Inc. | Trispecific antibodies |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1392359T4 (da) | 2001-05-11 | 2013-06-10 | Ludwig Inst For Cancer Res Ltd | Specifikke bindingsproteiner og deres anvendelser. |
| CA2832136C (en) * | 2002-09-27 | 2015-11-17 | Xencor | Optimized fc variants and methods for their generation |
| WO2007002223A2 (en) * | 2005-06-20 | 2007-01-04 | Medarex, Inc. | Cd19 antibodies and their uses |
| US8679502B2 (en) | 2007-11-13 | 2014-03-25 | Evec Inc. | Monoclonal antibodies that bind to HGM-CSF and medical compositions comprising same |
| US9365644B2 (en) * | 2008-04-23 | 2016-06-14 | Epitomics, Inc. | Anti-TNFα antibody |
| BRPI1014089A2 (pt) | 2009-04-02 | 2016-04-19 | Roche Glycart Ag | anticorpos multiespecíficos que compreendem anticorpos de comprimento completo e fragmentos fab de cadeia simples |
| GB201020995D0 (en) * | 2010-12-10 | 2011-01-26 | Bioinvent Int Ab | Biological materials and uses thereof |
| CN103906533A (zh) * | 2011-11-07 | 2014-07-02 | 米迪缪尼有限公司 | 多特异性和多价结合蛋白及其用途 |
| PL3489261T3 (pl) * | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| US9732150B2 (en) * | 2013-03-14 | 2017-08-15 | Alderbio Holdings Llc | Therapeutic use of antibodies to HGF |
| HK1218549A1 (zh) | 2013-06-26 | 2017-02-24 | Numab Therapeutics AG | 新型抗体框架 |
| JP6693872B2 (ja) * | 2013-07-25 | 2020-05-13 | シトムクス セラピューティクス,インコーポレイティド | 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法 |
| WO2015058861A1 (en) | 2013-10-25 | 2015-04-30 | Numab Ag | Bispecific constructs and their use in the treatment of various diseases |
| CA3265373A1 (en) * | 2014-02-20 | 2025-10-30 | H. Lundbeck A/S | Anti-acth antibodies and use thereof |
| UA117289C2 (uk) * | 2014-04-02 | 2018-07-10 | Ф. Хоффманн-Ля Рош Аг | Мультиспецифічне антитіло |
| EP3253790A4 (en) * | 2015-02-06 | 2018-07-25 | University of Maryland, Baltimore | Tetra-specific, octameric binding agents and antibodies against clostridium difficile toxin a and toxin b for treatment of c. difficile infection |
| CN104829733B (zh) * | 2015-05-25 | 2018-06-05 | 广州百暨基因科技有限公司 | 抗原结合单元稳定的嵌合抗原受体及制备方法与应用 |
| JP6932700B2 (ja) * | 2015-09-15 | 2021-09-08 | アムジエン・インコーポレーテツド | 4価の二重特異性抗原結合タンパク質及び4価の四重特異性抗原結合タンパク質、ならびにそれらの使用 |
| TW201904588A (zh) * | 2017-06-25 | 2019-02-01 | 美商西雅圖免疫公司 | 引導及導航控制蛋白質之製造及使用方法 |
| SG11201912865VA (en) | 2017-06-25 | 2020-01-30 | Systimmune Inc | Multi-specific antibodies and methods of making and using thereof |
| EP3773621A4 (en) * | 2018-03-27 | 2022-03-23 | Systimmune, Inc. | GUIDANCE AND NAVIGATION CONTROL PROTEINS AND METHODS FOR THEIR MANUFACTURE AND USE |
-
2018
- 2018-06-22 US US16/615,122 patent/US11787863B2/en active Active
- 2018-06-22 SG SG11201912864SA patent/SG11201912864SA/en unknown
- 2018-06-22 KR KR1020257003259A patent/KR20250024104A/ko active Pending
- 2018-06-22 CN CN202310141321.2A patent/CN116199785A/zh active Pending
- 2018-06-22 IL IL313468A patent/IL313468A/en unknown
- 2018-06-22 EP EP18825293.6A patent/EP3645049A4/en active Pending
- 2018-06-22 IL IL271257A patent/IL271257B2/en unknown
- 2018-06-22 JP JP2020520429A patent/JP7399852B2/ja active Active
- 2018-06-22 CN CN201880039401.4A patent/CN110831973B/zh active Active
- 2018-06-22 KR KR1020207002328A patent/KR102763369B1/ko active Active
- 2018-06-22 CN CN202310141062.3A patent/CN116041530A/zh active Pending
- 2018-06-22 AU AU2018295118A patent/AU2018295118B2/en active Active
- 2018-06-22 CN CN202310922275.XA patent/CN116948035A/zh active Pending
- 2018-06-22 WO PCT/US2018/039156 patent/WO2019005639A2/en not_active Ceased
- 2018-06-22 CA CA3068045A patent/CA3068045A1/en active Pending
-
2025
- 2025-06-27 AU AU2025204860A patent/AU2025204860A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102448985A (zh) * | 2009-05-27 | 2012-05-09 | 霍夫曼-拉罗奇有限公司 | 三或四特异性抗体 |
| US20160355600A1 (en) * | 2014-12-22 | 2016-12-08 | Xencor, Inc. | Trispecific antibodies |
Non-Patent Citations (2)
| Title |
|---|
| THOMAS KÖHNKE等: "Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab", 《JOURNAL OF HEMATOLOGY & ONCOLOGY》, vol. 8, 8 October 2015 (2015-10-08), pages 1 - 5 * |
| 锡建中等: "广义新型抗体的研究进展", 《黑龙江畜牧兽医》, no. 23, 10 December 2014 (2014-12-10), pages 60 - 62 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018295118A1 (en) | 2020-02-06 |
| IL271257B2 (en) | 2024-11-01 |
| US20220002406A1 (en) | 2022-01-06 |
| KR20200092301A (ko) | 2020-08-03 |
| CN116948035A (zh) | 2023-10-27 |
| IL313468A (en) | 2024-08-01 |
| CN116041530A (zh) | 2023-05-02 |
| EP3645049A2 (en) | 2020-05-06 |
| EP3645049A4 (en) | 2021-06-30 |
| KR20250024104A (ko) | 2025-02-18 |
| RU2020102662A (ru) | 2021-07-27 |
| WO2019005639A2 (en) | 2019-01-03 |
| AU2018295118B2 (en) | 2025-04-17 |
| KR102763369B1 (ko) | 2025-02-05 |
| WO2019005639A3 (en) | 2019-02-07 |
| JP2020530777A (ja) | 2020-10-29 |
| SG11201912864SA (en) | 2020-01-30 |
| US11787863B2 (en) | 2023-10-17 |
| IL271257B1 (en) | 2024-07-01 |
| JP7399852B2 (ja) | 2023-12-18 |
| CN110831973A (zh) | 2020-02-21 |
| CN110831973B (zh) | 2023-08-15 |
| NZ760913A (en) | 2024-10-25 |
| AU2025204860A1 (en) | 2025-07-17 |
| CA3068045A1 (en) | 2019-01-03 |
| IL271257A (en) | 2020-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7685095B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| CN111148761B (zh) | 多特异性抗体及其制备和使用方法 | |
| JP7399852B2 (ja) | 多重特異性抗体とその作製及び使用方法 | |
| JP7464764B2 (ja) | 抗ror1抗体とその作製及び使用方法 | |
| US20240279333A1 (en) | Multi-specific antibodies and methods of making and using thereof | |
| HK40088417A (en) | Multi-specific antibodies and methods of making and using thereof | |
| HK40088418A (en) | Multi-specific antibodies and methods of making and using thereof | |
| HK40093821A (en) | Multi-specific antibodies and methods of making and using thereof | |
| HK40111323A (en) | Multi-specific antibodies and methods of making and using thereof | |
| HK40111322A (en) | Multi-specific antibodies and methods of making and using thereof | |
| HK40018991A (en) | Multi-specific antibodies and methods of making and using thereof | |
| HK40019010A (en) | Multi-specific antibodies and methods of making and using thereof | |
| KR20260013450A (ko) | 이중 특이적 항원 결합 분자 및 이의 응용 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40088418 Country of ref document: HK |
|
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20240630 Address after: No. 139 Baili Road, Chengdu Cross Strait Science and Technology Industry Development Park, Wenjiang District, Chengdu City, Sichuan Province, 611130 Applicant after: Chengdu bailidote Biological Pharmaceutical Co.,Ltd. Country or region after: China Address before: 15318 Northeast 95th Street, Redmond, Washington, USA Applicant before: Seattle Immunization Co. Country or region before: U.S.A. Applicant before: Chengdu bailidote Biological Pharmaceutical Co.,Ltd. Country or region before: China |